Genoa Pharmaceuticals Inc. and McMaster University announced a plan to collaborate on idiopathic pulmonary fibrosis (IPF) research.
San Diego-based Genoa, which works in the field of pulmonary fibrosis, will work with researchers to characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF.
"We are very interested to evaluate novel therapies such as GP-101 to better understand the molecular effects and in vivo relationship to the human disease," said Dr. Martin Kolb, associate professor in the Division of Respirology, within the Department of Medicine Pathology & Molecular Medicine at McMaster University in Canada.
The research will combine Genoa's expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.
"Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients," said Mark Surber, Ph.D., Genoa's founder, president and chief scientific officer. "Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF."